Status:

UNKNOWN

Electrical Brain Stimulation for Cognitive Impairment in Schizophrenia: a tDCS-fMRI Study

Lead Sponsor:

The National Brain Mapping Laboratory (NBML)

Collaborating Sponsors:

University of British Columbia

Ruhr University of Bochum

Conditions:

Schizophrenia

Cognitive Impairment

Eligibility:

All Genders

18-50 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to investigate the mechanism of action of transcranial electrical brain stimulation over the dorsolateral prefrontal cortex for cognitive impairment in schizophrenia. To d...

Detailed Description

Thirty schizophrenic patients will be recruited after meeting the inclusion criteria and will be randomly assigned to active and sham stimulation groups. A single session of concurrent prefrontal tDCS...

Eligibility Criteria

Inclusion

  • men or women (18-50 yrs old) with a DSM 5 SCZ diagnosis,
  • If female, negative urine pregnancy test
  • significant cognitive impairment (1 SD below the norm on the working memory/executive functioning task performance)
  • feasibility for tDCS interventions according to safety guidelines
  • stable medication regime especially the classical neuroleptics and all CNS-activating medications, if taken, 4-6 weeks before the experiment
  • fluency in the native language
  • right-handed
  • ability to provide informed consent.

Exclusion

  • pregnancy
  • alcohol or substance dependence
  • history of seizure
  • history of neurological disorder
  • history of head injury
  • Presence of ferromagnetic objects in the body that are contraindicated for MRI of the head (pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips, metallic prostheses, permanent eyeliner, implanted delivery pump, or shrapnel fragments) or fear of enclosed spaces). Eligibility will be determined by the "MRI Safety Screening Questionnaire" and verified, if necessary, by a radiology consultant.

Key Trial Info

Start Date :

February 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2024

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT05200962

Start Date

February 1 2022

End Date

August 1 2024

Last Update

November 13 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The National Brain Mapping Laboratory (NBML)

Tehran, Iran